GILD240809C77000
- 0.01
- -0.96-98.97%
Gilead Sciences Newsroom
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $72
Deutsche Bank Keeps Their Hold Rating on Gilead Sciences (GILD)
Gilead Sciences (GILD) Gets a Hold From Cantor Fitzgerald
Gilead Sciences: Hold Rating Affirmed Amid Mixed Performance and Cautious Outlook
Gilead Sciences Analyst Ratings
Morgan Stanley Raises Price Target on Gilead Sciences to $79 From $74, Keeps Equalweight Rating
Gilead Sciences Poised for Growth: A Strong Buy Rating With a $93 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Analysts' Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $76
Gilead Sciences (GILD) Receives a Buy From TD Cowen
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Gilead Sciences: A Balanced Outlook With Steady HIV Performance and Oncology Challenges Justifying a Hold Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)
Gilead Sciences Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75
Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)